drugset / Trial / NCT02244606
Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to compare the safety, pharmacokinetics, and efficacy of oral SCY-078 vs. standard-of-care following initial intravenous echinocandin therapy in the treatment of invasive candidiasis.
Timeline
- Start
- 2014-09
- Primary completion
- 2016-06
- Completion
- 2016-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Fluconazole | Small molecule | 400 mg | Oral |
| Subject | Ibrexafungerp | Small molecule | 500 mg | Oral |
| Subject | Ibrexafungerp | Small molecule | 750 mg | Oral |
| Comparator | Micafungin | Peptide | 100 mg | Intravenous |